Head-To-Head Comparison: Nihon Kohden (OTCMKTS:NHNKY) vs. Solana (NASDAQ:HSDT)

Nihon Kohden (OTCMKTS:NHNKY) and Solana (NASDAQ:HSDT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Profitability

This table compares Nihon Kohden and Solana’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nihon Kohden	6.08%	9.46%	6.68%
Solana	-1,427.15%	-67.57%	-24.09%

Institutional and Insider Ownership

0.1% of Nihon Kohden shares are owned by institutional investors. Comparatively, 18.6% of Solana shares are owned by institutional investors. 14.4% of Solana shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Nihon Kohden and Solana”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nihon Kohden	$1.56 billion	0.94	$95.79 million	$0.59	14.75
Solana	$6.02 million	16.88	-$40.89 million	($109.67)	-0.02

Nihon Kohden has higher revenue and earnings than Solana. Solana is trading at a lower price-to-earnings ratio than Nihon Kohden, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Nihon Kohden has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, Solana has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Nihon Kohden and Solana, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nihon Kohden	0	1	0	1	3.00
Solana	1	1	1	1	2.50

Solana has a consensus target price of $3.50, indicating a potential upside of 101.15%. Given Solana’s higher possible upside, analysts plainly believe Solana is more favorable than Nihon Kohden.

Summary

Nihon Kohden beats Solana on 8 of the 14 factors compared between the two stocks.

About Nihon Kohden

Nihon Kohden Corporation engages in development, manufacturing, sale, maintenance, and consultation of medical electronic equipment, and related systems and products in Japan, Americas, Europe, rest of Asia, and internationally. It offers physiological measuring equipment comprising electrocardiographs, electroencephalographs, and polygraphs for Cath-labs; patient monitoring systems, such as beside and central monitors; and treatment equipment including defibrillators, automated external defibrillators, ventilators, and pacemakers. The company also provides medical support system, which includes diagnostic and clinical information system; and in-vitro diagnostic equipment comprising hematology and clinical chemistry analyzers. In addition, it operates insurance brokerage and technology licensing business. The company was incorporated in 1951 and is headquartered in Shinjuku, Japan.

About Solana

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.